REFERENCES
- ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia 2002; 33: 159–167
- Campbell DM, MacGillivray I, Carr-Hill R. Preeclampsia in second pregnancy. Br J Obstet Gynecol 1985; 92: 131–140
- Sibai BM, Lindheimer M, Hauth J, Caritis S, vanDorsten P, Klebanoff M, MacPherson C, Landon M, Miodovnik M, Paul R, Meis P, Dombrowski M. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339: 667–671, [INFOTRIEVE], [CSA], [CROSSREF]
- Mendilcioglu I, Trak B, Uner M, Umit S, Kucukosmanoglu M. Acta Obstet Gynecol Scand 2004; 83: 1044–1048, [INFOTRIEVE], [CSA], [CROSSREF]
- Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet 2001; 357: 53–56, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang Y, Gy Y, Zhang Y, Lewis DF. Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol 2004; 190: 817–824, [INFOTRIEVE], [CSA], [CROSSREF]
- Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950–955, [INFOTRIEVE], [CSA], [CROSSREF]
- Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5–15, [INFOTRIEVE], [CSA]
- Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967; 93: 569–579, [INFOTRIEVE], [CSA], [CROSSREF]
- Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253–257, [CSA]
- Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584–1589, [INFOTRIEVE], [CSA]
- Kupferminc MJ, Eldor A, Steinmann N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9–13, [INFOTRIEVE], [CSA], [CROSSREF]
- Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902–905, [INFOTRIEVE], [CSA], [CROSSREF]
- Kingdom JC, Kaufmann P. Oxygen and placental villous development: origins of fetal hypoxia. Placenta 1997; 18: 613–621, [INFOTRIEVE], [CSA], [CROSSREF]
- Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991; 337: 1427–1431, [INFOTRIEVE], [CSA], [CROSSREF]
- Grandone E, Brancaccio V, Colaizzo D, Sciannamè N, Pavone G, Di Minno G, Margaglione M. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78: 371–375, [INFOTRIEVE], [CSA], [CROSSREF]
- Sanson BJ, Lensing AWA, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Bulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyah K, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecular-weight heparin in pregnancy: a sistematic review. Thromb Haemostasis 1999; 81: 668–672, [CSA]
- Fleiss J. The Design and Analysis of Clinical Experiments. John Wiley & Sons, New York 1986; 374
- Patterson RM, Gibbs CE, Wood RC. Birth weight percentile and neonatal outcome: recurrence of intrauterine growth retardation. Obstet Gynecol 1986; 68: 464–468, [INFOTRIEVE], [CSA]
- Bakketeig LS, Hwoffman HJ, Harley EE. The tendency to repeat gestational age and birth weight in successive births. Am J Obstet Gynecol 1979; 135: 1086–1103, [INFOTRIEVE], [CSA]
- Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie NE, Irgens LM. Fetal and maternal contributions to risk of preeclampsia: population based study. Br Med J 1998; 316: 1343–1347, [CSA]
- Duley L, Hendersonsmart D, Knitght M, king J. Anti-platelet drugs for prevention of preclampsia and its consequences. Br Med J 2001; 322: 329–333, [CSA]
- Leitich H, Egarter C, Husslein P, Kaider A, Schemper M. A meta-analysis of low-dose aspirin for the prevention of intrauterine growth retardation. Br J Obstet Gynaecol 1997; 104: 450–459, [INFOTRIEVE], [CSA]
- Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002; 186: 422–426, Erratum in: Am J Obstet Gynecol 2003; 189:244[INFOTRIEVE], [CSA], [CROSSREF]
- Mousa HA, Alfirevicl Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?. Hum Reprod 2000; 15: 1830–1833, [INFOTRIEVE], [CSA], [CROSSREF]
- Sikkema JM, Franx A, Bruinse HW, van der Wijk HW, de Valk HW, Nikkels PG. Placental pathology in early onset preeclampsia and intrauterine growth restriction in women with and without thrombophilia. Placenta 2002; 23: 337–342, [INFOTRIEVE], [CSA], [CROSSREF]
- Romero R. Can heparin prevent adverse pregnancy outcome?. J Mat Fetal Neo Med 2002; 12: 1–8, [CSA]
- Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, Greaves M, Vickers MA. Prothrombotic genotypes are not associated with Pre-eclampsia and gestational Hypertension: Results from a Large Population-based Study and systematic review. Thromb Haemost 2002; 87: 779–785, [INFOTRIEVE], [CSA]
- Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936–939, [INFOTRIEVE], [CSA]
- Leach RE, Kilburn B, Wang J, Liu Z, Romero R, Armant DR. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Dev Biol 2004; 266: 223–237, [INFOTRIEVE], [CSA], [CROSSREF]
- Leach RE, Romero R, Kim YM, Chaiworapongsa T, Kilburn B, Das SK, Johnson A, Qureshi F, Jacques S, Armant DR. Preeclampsia and expression of heparin-binding EGF-like growth-factor. Lancet 2002; 360: 1215–1219, [INFOTRIEVE], [CSA], [CROSSREF]
- Kwaan HC, Wang J, Boggio L, Weiss I, Grobman W. The thrombogenic effect of an inflammatory cytokine on throphoblast from women with preeclampsia. Am J Obstet Gynecol 2004; 191: 2142–2147, [INFOTRIEVE], [CSA], [CROSSREF]
- Redman CW, Sargent I. Latest advances in understanding preeclampsia. Science 2005; 308: 1592–1594, [INFOTRIEVE], [CSA], [CROSSREF]
- Girardi G. Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation. J Reprod Immunol 2005; 66: 45–51, [INFOTRIEVE], [CSA], [CROSSREF]